|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||50.26 - 50.82|
|52-week range||50.26 - 50.82|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||N/A|
|Earnings date||01 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||38.30|
Data is still scarce on latest COVID-19 boosters
Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying.
Yahoo Finance reporter Anjalee Khemlani shares the latest updates on Pfizer's COVID booster, which could soon be approved for children ages 5-11.